Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IGBA Raises Global Awareness With Biosimilars Week

International Campaign Will Run From 16-20 November

Executive Summary

A campaign aimed at raising awareness and educating international audiences about biosimilars will be run next week by the IGBA.

You may also be interested in...



Australia’s GBMA Emphasizes Biosimilars Amid Government Change

As Australia’s GBMA launches its latest Biosimilars Awareness Week – the last under a five-year education grant – the association says it is looking forward to “the dawn of a new era” as it begins working with the newly-elected Labor government.

IGBA Launches Global Biosimilars Week 2021

The IGBA has followed the success of its inaugural Global Biosimilars Week in November 2020 by launching the second incarnation of the initiative, running this week.

Australia Extends Biosimilar Education Efforts

Australia’s government has agreed to extend a successful biosimilar education initiative led by the local GBMA industry association.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB150424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel